Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, is pleased to
announce its CEO Maria Maccecchini, Ph.D. will present the
Company’s novel approach to treating PD at the University of
Pennsylvania Perelman School of Medicine’s Parkinson’s Disease and
Movement Disorders Center (PD&MDC). The talk, “Rethinking
Parkinson’s Disease”, takes place Monday, July 20, 2020 at 1:00
p.m. ET.
Recognized by the Parkinson’s Foundation as one
of 45 worldwide Centers of Excellence, the PD&MDC is one of the
largest of its kind in the country and the preeminent in the
Philadelphia region, providing care to thousands of patients each
year.
Dr. Maccecchini will discuss how high levels of
neurotoxic proteins begin a toxic cascade, leading to impaired
axonal transport, inflammation, nerve cell death and loss of
cognitive and motor functions in PD, AD and other neurodegenerative
diseases. Dr. Maccecchini will present data demonstrating
reversal of the toxic cascade in animals and humans using ANVS401,
Annovis Bio’s lead compound, as well as discuss the Company’s
latest Phase 2 clinical trial targeting early AD and PD, including
trial sites and clinical timelines.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and plan to commence a second Phase 2a study in PD and
AD patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024